BPG is committed to discovery and dissemination of knowledge
Review
Copyright ©The Author(s) 2025.
World J Diabetes. Dec 15, 2025; 16(12): 114395
Published online Dec 15, 2025. doi: 10.4239/wjd.v16.i12.114395
Table 1 Representative lipid-lowering agents effects on inflammatory and immunomodulatory biomarkers
Lipid-lowering ingredient
Lipid-modifying
Inflammation and immunomodulation
Curcumin-piperine[119]TG (decrease)Serum CRP (decrease)
Pan-PPAR agonist (lanifibranor)[120]TG (decrease); LDL-C (decrease); apolipoprotein A1 (decrease); HDL (increase)CRP (decrease)
Aqueous extract of Cichorium intybus seeds[121]TG (decrease)Glutathione catalase (decrease); superoxide dismutase (decrease); malondialdehyde (decrease); adiponectin (decrease); TNF-α (decrease); IL-1β (decrease)
Aqueous extract of Terminalia chebula[122]TG (decrease); LDL-C (decrease); TC (decrease); VLDL-C (decrease); HDL (increase)NO (decrease); GSH (decrease); MDA (decrease); hsCRP (decrease)
Rutin flavonoid supplement[123]TG (decrease); LDL-C (decrease); TC (decrease); HDL (increase)MDA (decrease); IL-6 (decrease)
L-citrulline supplementation[124]TG (decrease); HDL (increase)TNF-α (decrease); hs-CRP (decrease)
Nano-curcumin[125]Lipoprotein (a) (decrease)hs-CRP (decrease)
Ellagic acid[126]TG (decrease); LDL-C (decrease); TC (decrease)MDA (decrease); CRP (decrease); TNF-α (decrease); IL-6 (decrease); TAC (increase); GPx (increase); SOD (increase)
GLP1RA (exenatide)[127]TG (decrease); HDL (increase)CRP (decrease); IL-6 (decrease); TNF-α (decrease)
GLP1RA (orforglipron)[128]TG (decrease); LDL-C (decrease); ApoB (decrease); ApoC3 (decrease)hs-CRP (decrease)
Rosuvastatin/ezetimibe[129]LDL-C (decrease)Senescent CD8+ T cells (decrease); Treg (decrease); Naive to memory CD8+ T cell (increase)